A phase I/II study of the pan Bcl-2 inhibitor obatoclax mesylate plus bortezomib for relapsed or refractory mantle cell lymphoma
Goy, André, Hernandez-Ilzaliturri, Francisco J., Kahl, Brad, Ford, Peggy, Protomastro, Ewelina, Berger, MarkVolume:
55
Language:
english
Journal:
Leukemia & Lymphoma
DOI:
10.3109/10428194.2014.907891
Date:
December, 2014
File:
PDF, 178 KB
english, 2014